Amylyx Pharmaceuticals
Cambridge, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit amylyx.com and follow us on LinkedIn and Twitter. For investors, please visit investo
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 384
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (AMLX)
- Website
- amylyx.com
- Company page
Recent activity at Amylyx Pharmaceuticals
- : SEC 8-K (1.01): On September 8, 2026, Amylyx Pharmaceuticals, Inc. entered into a Manufacturing and Supply Agreement with Bachem Americas, Inc., concerning the manufacturing and supply of avexitide drug substance. This agreement necessitates the company to purchase a minimum quantity per year beginning 2028, with the supply price adjusted annually based on operational costs. The initial term is five years, with automatic renewals and specific termination rights. Additionally, on September 1, 2026, the company entered a term sheet with Polypeptide Group AG, which includes a $30 million upfront fee for capacity reservation and outlines terms for a definitive agreement. These agreements are critical for the company's supply chain strategy for avexitide, pending regulatory approvals.
- : SEC 8-K (1.01): On August 19, 2026, Amylyx Pharmaceuticals, Inc. entered into a Material Definitive Agreement with Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC for the issuance and sale of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. Additionally, the Underwriting Agreement includes a 30-day option for the Underwriters to purchase up to 2,113,500 additional shares. This transaction indicates a significant capital raising effort by the company, potentially to fund ongoing research or business operations, and enhances its liquidity position in the market.
- : Amylyx Pharmaceuticals Raises $500 Million in Public Offering
- : SEC 8-K (8.01): On August 18, 2026, Amylyx Pharmaceuticals, Inc. hosted a conference call with investors and analysts to discuss positive topline results from the LUCIDITY Phase 3 clinical trial. The trial evaluated the efficacy and safety of avexitide in participants suffering from post-bariatric hypoglycemia after undergoing Roux-en-Y gastric bypass surgery. The announcement signifies a potential advancement in treatment options for this specific patient population, reflecting favorable clinical outcomes that could have significant implications for the company's future strategic direction. Selected slides from the investor presentation detailing these results are attached as Exhibit 99.1.
- : SEC 8-K (8.01): On August 18, 2026, the Company announced positive topline results from its Phase 3 clinical trial named LUCIDITY, which evaluated the investigational drug avexitide in treating post-bariatric hypoglycemia (PBH). The trial successfully met its primary endpoint by demonstrating a 55% reduction in hypoglycemic events compared to placebo, indicating significant therapeutic potential for avexitide. The study involved 78 participants, randomized to receive either the drug or placebo, and was well-tolerated with mild to moderate adverse events. The Company intends to submit a New Drug Application to the FDA by the end of 2026, leveraging the favorable trial outcomes for further regulatory progress.
- : SEC 8-K (7.01): On March 24, 2026, Amylyx Pharmaceuticals, Inc. updated its corporate presentation for investors and analysts, reflecting the completion of enrollment in the Phase 3 LUCIDITY trial. Additionally, it includes updates to the exploratory analysis of the Phase 2 PREVENT study, which was previously presented at the ENDO 2025 Annual Meeting, and notes the completion of enrollment for Cohort 2 in the Phase 1 LUMINA trial. The company has attached a copy of the presentation as Exhibit 99.1. This update aims to provide stakeholders with recent developments regarding ongoing clinical trials, indicating the company's progression in their research efforts.
- : Amylyx Pharmaceuticals Announces Development Candidate AMX0318 in Collaboration with Gubra
- : SEC 8-K (8.01): On January 8, 2026, Amylyx Pharmaceuticals, Inc. announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate aimed at treating post-bariatric hypoglycemia and other rare diseases. This candidate was identified through a research collaboration with Gubra A/S, a company specializing in peptide-based drug discovery. Gubra stands to receive over $50 million in success-based milestone payments, along with mid-single digit royalties on global net sales. Additionally, the handover of the development candidate will trigger a milestone payment of $4 million to Gubra, highlighting the strategic partnership and potential financial implications for both firms.
- : SEC 8-K (8.01): On January 8, 2026, Amylyx Pharmaceuticals, Inc. announced the selection of AMX0318, a development candidate for post-bariatric hypoglycemia and other rare diseases. This selection was made through a collaboration with Gubra A/S, a company focusing on peptide-based drug discovery. As per the terms of the agreement, Gubra stands to gain over $50 million in success-based development and commercialization milestones, in addition to mid-single-digit royalties on global net sales. Furthermore, the handover of the candidate will trigger a milestone payment of $4 million to Gubra, indicating significant financial commitments and potential future earnings for both companies involved.
- : Amylyx Pharmaceuticals announces lifting of FDA hold on AMX0114 clinical trial to treat ALS.
Amylyx Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Post-IPO Equity | $500.0M |
| Jul 2021 | Series C | $135.0M |
| Jul 2020 | Venture | $30.0M |
| Jan 2020 | Venture | $14.8M |
| Dec 2019 | Seed | $937K |
Leadership
- Joshua Cohen, Executive Officer, Director
- Justin Klee, Executive Officer, Director
- Stephen Chubb, Director
- George Milne, Director
- Walter Gilbert, Director
- Isaac Cheng, Director
- Felix Coerper, Director
- Felix Coerper, Director
- Isaac Cheng, Director
- Walter Gilbert, Director
- George Milne, Director
- Stephen Chubb, Director
Verified email and direct lines for Amylyx Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Amylyx Pharmaceuticals files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Amylyx Pharmaceuticals in the news
- Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 - Business Wire (Aug 03, 2026)
- Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum - Business Wire (Sep 23, 2026)
- Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace (Aug 18, 2026)
- Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 - Yahoo Finance (Aug 17, 2026)
- Paul Fonteyne Joins Amylyx Pharmaceuticals Board of Directors - Amylyx (Mar 29, 2021)
- James Frates Joins Amylyx Pharmaceuticals as Chief Financial Officer - Amylyx (Jan 14, 2021)
- Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results - Business Wire (Aug 06, 2026)
- Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock - Business Wire (Aug 18, 2026)
Companies similar to Amylyx Pharmaceuticals
- Crinetics Pharmaceuticals · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Nuvalent · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Aquestive Therapeutics, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Madrigal Pharmaceuticals · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Biofrontera · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Amylyx Pharmaceuticals: questions and answers
What does Amylyx Pharmaceuticals do?
Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit amylyx.com and follow us on LinkedIn and Twitter. For investors, please visit investo
Where is Amylyx Pharmaceuticals headquartered?
Amylyx Pharmaceuticals is headquartered in Cambridge, Massachusetts, United States.
How many employees does Amylyx Pharmaceuticals have?
Amylyx Pharmaceuticals has about 384 employees.
Has Amylyx Pharmaceuticals raised funding?
Yes. Fundz has recorded 5 funding events for Amylyx Pharmaceuticals. The most recent, Post-IPO Equity of $500.0M, was in Aug 2026.
What is the latest news on Amylyx Pharmaceuticals?
On Sep 08, 2026, SEC 8-K (1.01): On September 8, 2026, Amylyx Pharmaceuticals, Inc. entered into a Manufacturing and Supply Agreement with Bachem Americas, Inc., concerning the manufacturing and supply of avexitide drug substance. This agreement necessitates the company to purchase a minimum quantity per year beginn
Is Amylyx Pharmaceuticals a public company?
Yes. Amylyx Pharmaceuticals is publicly traded under the ticker AMLX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy